BMY Bristol-Myers Squibb Company

  1. Stocks
  2. Healthcare
  3. NYSE: BMY

Price (delayed)

$63.02

Market cap

$128.82B

P/E Ratio

13.91

Dividend/share

$2.52

EPS

$4.53

Enterprise value

$162.12B

?
Relative Growth: Rel. Growth: 48
Relative Strength: Rel. Strength: 67
Relative Valuation: Rel. Valuation: 82
Relative Profitability: Rel. Profitability: 94

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Highlights
The net income has surged by 53% year-on-year
Bristol-Myers Squibb's EPS has surged by 53% YoY
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.bms.com
Peers: MRK LLY PFE NVS

Key stats

What are the main financial stats of BMY

BMY stock price

How has the Bristol-Myers Squibb stock price performed over time
Intraday
0.86%
1 week
2.29%
1 month
3.06%
1 year
36.79%
YTD
16.83%
QTD
0.99%

Financial performance

How have Bristol-Myers Squibb's revenue and profit performed over time
Revenue
$50.03B
Gross profit
$34.64B
Operating income
$11.33B
Net income
$9.24B
Gross margin
69.2%
Net margin
18.5%
The net income has surged by 53% year-on-year
BMY's net margin is up by 47% year-on-year but it is down by 2.1% since the previous quarter
The operating income rose by 41% year-on-year but it has declined by 4.9% since the previous quarter
The operating margin has increased by 35% year-on-year but it has declined by 7% since the previous quarter

Price vs fundamentals

How does BMY's price correlate with its fundamentals

Growth

What is Bristol-Myers Squibb's growth rate over time

Valuation

What is Bristol-Myers Squibb stock price valuation
BMY P/E details
P/E
13.91
P/B
5.5
P/S
2.57
EV/EBIT
14.31
EV/EBITDA
11.48
EV/Sales
3.24
Bristol-Myers Squibb's EPS has surged by 53% YoY
The stock's price to earnings (P/E) is 25% less than its 5-year quarterly average of 18.6 and 5% less than its last 4 quarters average of 14.7
Bristol-Myers Squibb's equity has increased by 26% YoY and by 4.9% from the previous quarter
BMY's P/B is 3.8% above its 5-year quarterly average of 5.3 but 3.5% below its last 4 quarters average of 5.7
The price to sales (P/S) is 7% more than the last 4 quarters average of 2.4
The company's revenue rose by 4.2% YoY

Efficiency

How efficient is Bristol-Myers Squibb business performance
Bristol-Myers Squibb's ROA has soared by 64% YoY
BMY's return on invested capital is up by 38% year-on-year but it is down by 7% since the previous quarter
Bristol-Myers Squibb's return on sales has increased by 35% YoY but it has decreased by 7% QoQ
The ROE has grown by 27% YoY but it has contracted by 6% from the previous quarter

Dividends

What is BMY's dividend history
Dividend details
DPS
$2.52
Dividend yield
4%
Payout ratio
55.6%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Bristol-Myers Squibb financials performed over time
BMY's total assets is 36% greater than its total liabilities
Bristol-Myers Squibb's current ratio has increased by 25% YoY and by 3.9% from the previous quarter
The quick ratio has increased by 25% YoY and by 7% QoQ
BMY's debt is 83% greater than its equity
The company's debt to equity fell by 31% YoY and by 5% QoQ
Bristol-Myers Squibb's equity has increased by 26% YoY and by 4.9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.